From: Exercise and obesity in fibromyalgia: beneficial roles of IGF-1 and resistin?
 |  | ∆MFIGF 30 wks | ∆Adiponectin 30 wks | ∆Leptin 30 wks | ∆Resistin 30 wks | ∆Free IGF-1 30 wks | ∆Total IGF-1 30 wks | ∆IGFB3 30 wks | ∆NGF 30 wks | ∆NPY 30 wks |
---|---|---|---|---|---|---|---|---|---|---|
∆FIQ fatigue 30 wks | r P n | 0.415 0.005 44 | -0.227 0.164 39 | -0.111 0.502 39 | -0.016 0.923 39 | -0.147 0.385 37 | 0.106 0.549 34 | 0.250 0.141 36 | -0.463 0.034 21 | 0.469 0.032 21 |
∆MFIGF 30 wks | r P n | 1.000 44 | -0.096 0.561 39 | 0.280 0.084 39 | -0.346 0.031 39 | -0.201 0.232 37 | -0.075 0.672 34 | 0.382 0.022 36 | 0.043 0.852 21 | 0.209 0.364 21 |
∆Adiponectin 30 wks | r P n |  | 1.000 41 | -0.016 0.922 41 | 0.011 0.943 41 | 0.002 0.989 39 | 0.091 0.600 36 | -0.241 0.145 38 | 0.097 0.669 22 | -0.361 0.099 22 |
∆Leptin 30 wks | r P n |  |  | 1.000 41 | -0.009 0.954 41 | -0.211 0.196 39 | 0.051 0.765 36 | -0.058 0.730 38 | 0.199 0.374 22 | -0.091 0.687 22 |
∆Resistin 30 wks | r P n |  |  |  | 1.000 41 | 0.048 0.770 39 | -0.186 0.277 36 | -0.143 0.393 38 | 0.103 0.647 22 | -0.278 0.210 22 |
∆Free IGF-1 30 wks | r P n |  |  |  |  | 1.000 40 | 0.103 0.556 35 | 0.178 0.299 36 | 0.356 0.104 22 | -0.563 0.006 22 |
∆Total IGF-1 30 wks | r P n |  |  |  |  |  | 1.000 40 | 0.043 0.812 33 | -0.115 0.639 19 | -0.128 0.601 19 |
∆IGFB3 30 wks | r P n |  |  |  |  |  |  | 1.000 38 | -0.089 0.695 22 | -0.242 0.277 22 |
∆NGF 30 wks | r P n |  |  |  |  |  |  |  | 1.000 22 | -0.215 0.336 22 |